Michel Dagenais

Suggest Changes
Learn More
PURPOSE To compare the selective matrix metalloproteinase inhibitor BAY 12-9566 with the nucleoside analog gemcitabine in the treatment of advanced pancreatic cancer. METHODS Patients with advanced(More)